title: Double-blind trial of omeprazole and amoxicillin in the cure of Helicobacter pylori infection in gastric ulcer patients. The Ulcer Study Group, Germany.
abstract: BACKGROUND
  Our aim was to investigate the efficacy of omeprazole and amoxicillin in curing Helicobacter pylori infection in gastric ulcer patients.
  
  
  METHODS
  In a double-blind trial 185 H. pylori-positive gastric ulcer patients were prospectively randomized to receive 40 mg omeprazole twice daily and either 750 mg amoxicillin three times daily or 750 mg amoxicillin placebo three times daily on days 1-14, followed by 20 mg omeprazole daily on days 15-56.
  
  
  RESULTS
  Twenty-seven patients were excluded because of lack of compliance or missed follow-up examinations; one patient receiving amoxicillin discontinued treatment owing to side effects. On an intention-to-treat basis, omeprazole/amoxicillin led to cure of H. pylori infection in 67.1% (47 of 70) of patients not using non-steroidal anti-inflammatory drugs (NSAIDs)/aspirin (ASA) and in 46.7% (14 of 30) of those taking NSAIDs/ASA (P < 0.05). With the omeprazole/placebo regimen, H. pylori infection was cured in 8.8% (no NSAIDs), and 0% (NSAIDs).
  
  
  CONCLUSIONS
  The use of NSAIDs/ASA may limit the efficacy of omeprazole/amoxicillin in curing H. pylori infection in gastric ulcer patients.
authors.affiliation: Medical Dept. II, Klinikun Grosshadern, University of Munich, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Meining
authors.forename: W
authors.initials: W
authors.lastname: Höchter
authors.forename: J
authors.initials: J
authors.lastname: Weingart
authors.forename: A
authors.initials: A
authors.lastname: Sommer
authors.forename: H
authors.initials: H
authors.lastname: Klann
authors.forename: T
authors.initials: T
authors.lastname: Simon
authors.forename: F
authors.initials: F
authors.lastname: Huber
authors.forename: K H
authors.initials: KH
authors.lastname: Bolle
authors.forename: R
authors.initials: R
authors.lastname: Hatz
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: N
authors.initials: N
authors.lastname: Lehn
authors.forename: M
authors.initials: M
authors.lastname: Stolte
authors.forename: E
authors.initials: E
authors.lastname: Bayerdörffer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D011446:Prospective Studies; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D010406:Penicillins; D000658:Amoxicillin; D009853:Omeprazole